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Quaking promotes monocyte differentiation
into pro-atherogenic macrophages by controlling
pre-mRNA splicing and gene expression
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A hallmark of inﬂammatory diseases is the excessive recruitment and inﬂux of monocytes to
sites of tissue damage and their ensuing differentiation into macrophages. Numerous stimuli
are known to induce transcriptional changes associated with macrophage phenotype, but
posttranscriptional control of human macrophage differentiation is less well understood. Here
we show that expression levels of the RNA-binding protein Quaking (QKI) are low in
monocytes and early human atherosclerotic lesions, but are abundant in macrophages of
advanced plaques. Depletion of QKI protein impairs monocyte adhesion, migration,
differentiation into macrophages and foam cell formation in vitro and in vivo. RNA-seq and
microarray analysis of human monocyte and macrophage transcriptomes, including those of a
unique QKI haploinsufﬁcient patient, reveal striking changes in QKI-dependent messenger
RNA levels and splicing of RNA transcripts. The biological importance of these transcripts
and requirement for QKI during differentiation illustrates a central role for QKI in
posttranscriptionally guiding macrophage identity and function.
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M
onocytes serve as danger sensors within the circulation.
The activation of blood-borne monocytes by
inﬂammatory stimuli triggers their adhesion and
homing to sites of tissue injury, where they differentiate into
macrophages and collectively aid in the resolution of damage1,2.
However, the chronic accumulation of macrophages at these sites
of injury is a hallmark of inﬂammatory diseases such as
rheumatoid arthritis3, Crohn’s disease4 and atherosclerosis5–7.
Dynamic changes in gene expression are associated with
monocyte to macrophage differentiation, where PU.1 (ref. 8),
Signal Transducer and Activator of Transcription (STATs)9 and
CCAAT/Enhancer Binding Protein (C/EBP)s10 are key
transcription factors that drive this alteration in cellular
phenotype and function11,12. Importantly, numerous studies
have identiﬁed critical roles for both microRNAs (miRNAs)
and RNA-binding proteins (RBPs) in posttranscriptionally
regulating monocyte13 and macrophage14 biology. However, the
posttranscriptional regulation of monocyte to macrophage
differentiation has generally been limited to studies detailing
miRNA-based targeting of individual transcription factors or
effector molecules that either stimulate or delay this phenotypic
conversion15–17.
In contrast to miRNAs, RBPs mediate both quantitative and
qualitative changes to the transcriptome, interacting with
pre-mRNAs to inﬂuence (alternative) splicing, transcript stability,
editing, subcellular localization and translational activation or
repression18–20. This broad arsenal of RNA-based control
points enables RBPs to modulate the proteome in response to
immunogenic stimuli17, shifting inﬂammatory cells from an
immature or naive state to a mature or activated state, as has
previously been established in lymphoid cells21,22. In recent times,
we discovered that expression of the RBP Quaking (QKI) is
induced in human restenotic lesion-resident vascular smooth
muscle cells (VSMCs), where it directly mediates a splicing event
in the Myocardin pre-mRNA that governs VSMC function23.
This ﬁnding prompted us to investigate whether QKI could
similarly serve as an inﬂammation-sensitive posttranscriptional
guide during monocyte to macrophage differentiation. Alter-
native splicing of the QKI pre-mRNA yields mature transcripts of
5, 6 or 7 kb that encode distinct protein isoforms, namely QKI-5,
-6 and -7 (refs 24,25). QKI-5 possesses a nuclear locali-
zation signal in the carboxy-terminal region and is found
in the nucleus of cells. In contrast, QKI-6 and QKI-7 are found
in the cytoplasm. However, QKI-6 and QKI-7 can also translocate
to the nucleus23,26. The presence of a KH-family homology
domain confers QKI with the capacity to bind RNA27, albeit
dimerization is required26,28 to bind with high afﬁnity to the QKI
response element (QRE) sequence (NACUAAY N1-20 UAAY)
on target RNAs29–33. Importantly, aberrant QKI expression is
associated with inﬂammatory diseases such as schizophrenia34,35,
cancer36 and restenosis23.
Here we show that the RBP QKI plays a critical role in
regulating the conversion of monocytes into macrophages in,
for example, atherosclerotic lesions. Our studies pinpoint QKI as
a dynamic regulator of pre-mRNA splicing and expression
proﬁles that drive monocyte activation, adhesion and
differentiation into macrophages, and facilitates their conversion
into foam cells.
Results
Human atherosclerotic lesion macrophages express QKI. We
previously observed QKI expression in VSMCs23 and in leukocyte
foci within human coronary restenotic lesions. Based on this
observation, we used laser-capture microdissection to harvest
CD68þ macrophages from early and advanced atherosclerotic
lesions of human carotid arteries. QKI mRNA was 4.2-fold
enriched in macrophages derived from advanced as compared
with early atherosclerotic lesions (Fig. 1a). Next, using
immunohistochemistry, we assessed QKI protein expression in
human tissue sections at various stages of atherosclerotic lesion
development, namely early pathological intimal thickening (PIT),
ﬁbrous cap atheroma (FCA) and intraplaque haemorrhaging
(IPH). Although QKI was detectable in CD68þ myeloid cells
of PIT, it was abundantly expressed in macrophage-rich FCA
and IPH lesions (Fig. 1b). Furthermore, QKI-5, -6 and -7 were
detectable in the nuclear, perinuclear and cytoplasmic regions of
intimal macrophages in both FCA and IPH, respectively (Fig. 1c).
We conclude that the accumulation of macrophages in human
atherosclerotic lesions is associated with increased mRNA
and protein expression of all three QKI isoforms within the
macrophage.
A reduction in QKI decreases lesional macrophage burden. To
investigate whether decreased QKI expression in monocytes and
macrophages could inﬂuence atherosclerotic lesion formation, we
transplanted bone marrow (BM) from QKI viable (qkv) mice37,
which express reduced levels of QKI protein, or their wild-type
(wt) littermate controls (LM) into atherogenic LDLR / mice.
Although qk knockout mice die as embryos, the qkv mouse
harbours a spontaneous B1Mb deletion in the QK promoter
region that leads to reduced levels of QKI mRNA and protein37.
Indeed, macrophage colony-stimulating factor (M-CSF)-
mediated conversion of LM and qkv BM-derived monocytes to
macrophages showed subtly reduced QKI-5 mRNA and protein
levels, and almost a complete ablation of QKI-6 and -7 protein
(Fig. 1d,e). Following BM transplantation, the LDLR / /qkv and
LDLR / /LM mice were fed a high-fat diet for 8 weeks, to
induce atherosclerotic lesion formation. Interestingly, the long-
term reduction of QKI expression during haematopoietic
reconstitution limited neutrophil and monocytic repopulation
(Supplementary Data 1). In keeping with this ﬁnding,
immunohistochemical analysis of the aortic root revealed
signiﬁcantly decreased monocyte/macrophage content within
atherosclerotic lesions of LDLR / /qkv mice (Fig. 1f), a
ﬁnding that immunohistochemical analysis revealed was
independent of plaque size or collagen content. These ﬁndings
suggested that changes in haematopoietic and monocytic QKI
expression could inﬂuence the macrophage content of
atherosclerotic lesions.
QKI is induced on monocyte to macrophage differentiation.
Having identiﬁed high QKI expression in macrophages in
atherosclerotic lesions, we ﬁrst explored whether QKI mRNA
expression levels differ in macrophage precursors, namely classical
(CD14þþ /CD16 ), intermediate (CD14þþ /CD16þ ) and
non-classical (CD14þ /CD16þ ) monocytes derived from human
peripheral blood (PB)2. All three monocyte subpopulations
abundantly expressed QKI-5, -6 and -7 mRNAs as compared
with glyceraldehyde 3-phosphate dehydrogenase (Fig. 2a).
Moreover, QKI-5, -6 and -7 mRNA levels increased as classical
monocytes progressed towards intermediate or non-classical
monocytes. Interestingly, QKI-5 mRNA was the most abundantly
expressed transcript in all three subpopulations. (Fig. 2a).
Next, we assessed QKI mRNA and protein levels in human PB
monocytes treated with granulocyte–macrophage CSF (GM-CSF)
and M-CSF, to stimulate their conversion to pro-inﬂammatory
and anti-inﬂammatory macrophages, respectively (Fig. 2b). We
observed remarkable increases in the expression of all QKI
mRNA transcripts in mature macrophages (Fig. 2c). However,
despite abundant QKI mRNA, the distinct QKI isoforms
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Figure 1 | Quaking is expressed in macrophages within atherosclerotic lesions. (a) Pan-QKI mRNA expression levels in CD68þ macrophages of early
and advanced atherosclerotic lesions isolated by laser-capture microdissection (n¼4). Data expressed as mean±s.e.m.; Student’s t-test, *Po0.05. Scale
bar, 50mm. (b) Immunohistochemical analysis of co-localization of pan-QKI and CD68 expression in preliminary intimal thickening (PIT), FCA and
intraplaque haemorrage (PIH). Dashed line denotes intimal/adventitial border. Scale bar, 50mm. (c) Immunohistochemical analysis of QKI-5, -6 and -7
expression in PIT, FCA and IPH (top), and quantiﬁcation of QKI-positive cells mm2 per tissue sample (n¼ 5). Data expressed as mean±s.e.m.; one-way
analysis of variance (ANOVA), Bonferroni’s post-hoc test; *Po0.05, **Po0.01. (d) Quantitative RT–PCR (qRT–PCR) analysis of QKI mRNA expression in
naive BM-derived CD115þ mouse monocytes and 7 days M-CSF stimulated macrophages of either wt-littermates (LM) or quaking viable (qkv) mice
(n¼ at least 3 mice per condition). Data expressed as mean±s.e.m.; one-way ANOVA, Bonferroni’s post-hoc test; *Po0.05 and **Po0.01. (e) Western
blot analysis of QKI-5, -6 and -7 expression levels in 7 days M-CSF stimulated macrophages derived from BM of wt and qkv mice. Each lane represents an
individual mouse lysate (biological n¼ 3). (f) Immunohistochemical analysis for atherosclerotic plaque-resident macrophages (% MoMa-positive area) in
aortic root sections of g-irradiated (8Gy) LDLR / mice that subsequently were transplanted with BM from either qkv mice (qkv-BM) or littermates
(LM)(LM-BM) and fed a high-fat diet for 8 weeks to develop atherosclerotic lesions (n¼ 12 per group). Scale bar, 200mm. Data expressed as
mean±s.e.m.; Student’s t-test, with *Po0.05.
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were poorly expressed in freshly isolated PB monocytes as
compared with mature macrophages (Fig. 2d). The GM-CSF or
M-CSF-induced conversion of monocytes into macrophages was
associated with striking increases in QKI-5, -6 and -7 protein
levels, with a more pronounced increase in all three isoforms
observed with M-CSF treatment (Fig. 2d).
QKI haploinsufﬁciency perturbs macrophage differentiation.
To further assess the role of QKI in monocyte and macrophage
biology, we undertook an in-depth analysis of a unique, QKI
haploinsufﬁcient individual (Pat-QKIþ / ) and her sister control
(Sib-QKIþ /þ )38. This patient is the only known carrier of a
balanced reciprocal translocation (t(5;6)(q23.1;q26)), where a
breakpoint in one of her QKI alleles speciﬁcally reduces QKI
expression by 50% in both QKI mRNA38 and QKI protein
levels as compared with her sibling (Sib-QKIþ /þ ; Fig. 3a,b).
RNA sequencing (RNA-seq) analysis (see below) conﬁrmed
altered QKI expression and furthermore revealed the precise
location of the translocation breakpoint in intron 4 of QKI
(Fig. 3b and Supplementary Fig. 1a).
We next compared the circulating monocytes of these two
individuals for the expression of well-established monocyte
cell surface markers such as CD14, CD16, CX3CR1, CCR2,
SELPLG and CSF1R by ﬂuorescence-activated cell sorting (FACS)
analysis. Although monocyte subset ratios were not different
(Supplementary Fig. 2a), the expression of CSF1R, the
receptor that drives macrophage commitment, was elevated
in Pat-QKIþ / non-classical monocytes as compared with
Sib-QKIþ /þ (Supplementary Fig. 2b). As CSF1R is normally
reduced when monocytes differentiate into macrophages, this
observation points towards a potential defect in monocyte
maturation in the patient.
Next, we investigated the consequences of decreased QKI
expression on monocyte to macrophage differentiation. For this,
we obtained freshly isolated Pat-QKIþ / and Sib-QKIþ /þ
monocytes from venous blood and treated the cells for 7 days
in the presence of either GM-CSF or M-CSF. Similar to the results
in Fig. 2b, Sib-QKIþ /þ monocytes possessed the capacity to
adopt the characteristic pro-inﬂammatory macrophage
morphology, whereas monocytes from Pat-QKIþ / generally
retained a monocytic morphology (Fig. 3c top panels). We
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harvested RNA and protein from these macrophages and
found that both QKI mRNA and protein levels were
decreased (Fig. 3d,e). Surprisingly, this reduction in QKI did
not appear to have an impact on the conversion of monocytes
into anti-inﬂammatory macrophages (Fig. 3c bottom panels), a
ﬁnding that prompted us to focus on the role of QKI in
monocyte to macrophage differentiation in a pro-inﬂammatory
setting.
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QKI impacts transcript abundance in monocytes and macro-
phages. The observed increase in QKI expression during
macrophage differentiation and well-established function as a
splicing and translational regulator23,31,39,40 suggested that QKI is
necessary for posttranscriptional control of events that lead to
macrophage identity. To identify potential regulatory targets of
QKI at a genome-wide level, we characterized the trans-
criptomes of Sib-QKIþ /þ and Pat-QKIþ / monocytes and
GM-CSF-stimulated macrophages by RNA-seq (Supplementary
Data 2). First, we assessed the expression levels of established
immune-regulated genes11,12. As shown in Fig. 3f, the mRNA
levels of many monocyte to macrophage differentiation
markers11,12 were similarly regulated in Sib-QKIþ /þ and
Pat-QKIþ / (CD68m, ApoEm, ITGAMm, CD14k, CX3CR1k
and CD163k). In contrast, the expression levels of several key
pro- and anti-inﬂammatory markers indicated an anti-
atherogenic shift in Pat-QKIþ / macrophages (Fig. 3f right;
IL6k, IL23ak, CD16Ak, CD16Bk, ApoEk and IL10m). At the
genome-wide level, QKI haploinsufﬁciency altered the abundance
of 2,433 and 1,306 mRNA species in monocytes and macrophages
(Fig. 3g, Supplementary Data 2 and Supplementary Fig. 3 top),
respectively. Subsequently, we computationally determined the
subset of mature mRNA transcripts in the genome that contain a
QKI-binding sequence motif (termed QRE)30 (Supplementary
Data 2). Our data suggested that QKI directly modulates the
expression of 215 (128m and 87k) and 154 (100m and 54k)
mRNAs in PB monocytes and macrophages, respectively (Fig. 3g,
Venn sum of intersect). The ﬁve most differentially expressed
genes in the patient relative to the sibling that harbour a QRE are
shown in Fig. 3h. By selecting genes containing QREs, we
identiﬁed a substantial number of putative QKI-mediated
changes in transcript abundance (Fig. 3i).
Previous genome-wide studies have reported contrasting roles
for QKI as both a repressor and stabilizer of target mRNAs31,33.
Intrigued by this ambiguity, we determined the consequences of
QKI haploinsufﬁciency on mRNA transcript abundance in
monocytes and macrophages. For this, we tested whether the
presence of a QRE within a target mRNA was associated with
increased or decreased mRNA abundance in the patient relative
to her sibling (Supplementary Fig. 3 top). For this, we plotted the
cumulative distribution fraction (CDF: y axis, as a fraction of total
genes) against the transcript Log2FC (x axis: Pat-QKIþ / /
Sib-QKIþ /þ ) and stratiﬁed for either putative QKI targets (with
QRE) or non-targets (no QRE). In PB monocytes, a reduction in
QKI was associated with signiﬁcantly lowered target mRNA
expression (Fig. 3j left panel, left shift of cyan line). In contrast, in
PB macrophages the expression levels of mature mRNAs
containing QREs was strikingly increased in the patient relative
to her sibling, as compared with those without QREs (Fig. 3j right
panel, right shift of cyan line). Collectively, these studies
suggested that QKI potently regulates gene expression during
monocyte-to-macrophage differentiation.
QKI controls splicing in monocytes and macrophages.
Given previous reports that QKI is involved in splicing of
pre-mRNAs23,39–42, we tested whether QKI acts similarly in
monocytes and macrophages. First, we evaluated our RNA-seq
analysis of Sib-QKIþ /þ and Pat-QKIþ / PB monocytes and
macrophages for splicing changes (Supplementary Data 3). This
analysis uncovered 1,513 alternative splicing events between
Pat-QKIþ / and Sib-QKIþ /þ monocytes and macrophages,
revealing events that were unique to either monocytes or
macrophages, as well as common events (Supplementary Data
3). Previous observations for QKI and other RBPs suggested that
when a splicing factor binds the intron downstream of an
alternative exon, it promotes exon inclusion; however, when
binding the intron upstream of the alternative exon, the RBP
promotes exon skipping19,43. We analysed the RNA-seq data for
such a trend using the set of splicing events that change between
the Pat-QKIþ / and Sib-QKIþ /þ , to determine the frequency
of the QKI-binding motif, ACUAA, around these regulated
exons, relative to a background set of exons that is expressed, but
inclusion is unchanged between the two data sets. The results of
these analyses are shown in Fig. 4a and Supplementary Data 4,
and demonstrate ACUAA motif enrichment upstream of exons
with increasing inclusion in Pat-QKIþ / (QKI repressed exons)
relative to background exons, as well as an increase in ACUAA
motif frequency downstream of exons with increased skipping
(QKI activated) relative to background. This suggested that
similar to C2C12 myoblasts39, QKI promotes exon skipping by
binding the upstream intron, while promoting inclusion of
alternative exons by binding to the downstream intron, in
monocytes and in macrophages. These data strongly support a
direct, position-dependent role for QKI in regulating alternative
splicing, while also providing additional protein diversity during
monocyte-to-macrophage differentiation.
As shown in Fig. 4b, QKI haploinsufﬁciency triggered
alternative splicing events in PB monocytes (orange tracks) and
macrophages (blue tracks). Interestingly, the presence of
QKI-binding sites, as deﬁned by either experimentally deter-
mined QKI PAR-CLIP sites39 and/or ACUAA motifs clearly
Figure 3 | Characterization of monocyte and macrophage biology in a unique QKI haploinsufﬁcient patient. (a) Schematic of chromosomal translocation
event in the qkI haploinsufﬁcient patient (Pat-QKIþ / ), reducing QKI expression to B50% that of her sister control (Sib-QKIþ /þ ). (b) Top: UCSC
Genome Browser display of reference genome QKI locus with standard and chimeric reads for the patient and sibling. The reduced expression levels
and altered 30-untranslated region (UTR) composition in the patient RNA as compared with a sibling control is noteworthy. Patient shows increased
intronic RNA extending to the point where chimeric reads map at the breakpoint to chr5. Middle: chromosome diagrams showing normal chromosomes 5
and 6 with the red line, indicating the location of the breakage fusion point. Bottom: sequence across the fusion point. The chromosomal origin of
the AG dinucleotide is ambiguous. (c) Photomicrographs of sibling and patient macrophages, cultured in GM-CSF or M-CSF for 7 days, respectively.
(d,e) Assessment of QKI isoform mRNA and protein expression in 4-day GM-CSF-stimulated macrophages in the sibling and patient. (f) Hierarchical
clustering (Euclidean algorithm) of key monocyte differentiation genes depicting changes in RNA-seq-derived mRNA abundance where dark
blue¼ low expression, whereas light blue¼ high expression (* and/or # indicates Z1.5-fold expression change in monocytes or macrophages,
respectively). (g) Venn diagrams with numbers of differentially expressed genes (minimally±1.5-fold; patient/sibling expression) for unstimulated (top)
and GM-CSF stimulated macrophages (bottom). An expression cutoff (Patþ Sib expressionZ1CPM) was applied. (h) The most differentially expressed
genes, harbouring a QRE are depicted. (i) Genome-wide scatterplot of mRNA abundance (y axis: Log10 CPM) versus the log2FC (x axis: Patient/sibling
CPM) after an expression cutoff (Patþ Sib expression Z1 CPM) in monocytes (left) and GM-CSF-stimulated macrophages (right). Blue dots indicate
QRE-containing transcripts minimally ±1.5-fold differentially expressed. Grey dots do not fulﬁll these criteria. (j) CDF (y axis) for QKI target
(QRE containing: blue line) and non-target (non-QRE containing: cyan line) mRNAs (x axis: log2FC) in monocytes (left) and macrophages (right). Left shift
indicates lower expression of QKI target genes, whereas a right shift indicates higher expression of QKI targets in the patient samples. Distributions were
compared using a Wilcoxon rank-sum test.
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Figure 4 | QKI inﬂuences pre-mRNA splicing in naive PB monocytes and macrophages. (a) SpliceTrap assessment of the proximal ACUAA RNA motif
enrichment in 50-bp windows upstream and downstream of alternatively spliced cassette exons (as compared with a background set of exons; grey
circles). The relationship between the frequency of exon exclusion (blue triangles) or exon inclusion (red squares) and ACUAA RNA motif enrichment over
the genomic locus are depicted. (b) Sashimi plots illustrate RNA-seq read coverage for selected alternative splicing events in Pat-QKIþ / versus Sib-
QKIþ /þ PB monocytes (orange) and macrophages (blue). Splicing events (se) are highlighted by inverted brackets. The location of ACUAA motifs and
QKI PAR-CLIPs are provided below. Splicing events were deﬁned based on the genomic organization of RefSeq transcripts (bottom tracks). Full event details
are provided in Supplementary Data 3. (c) PCR validation of alternatively spliced cassette exons in Sib-QKIþ /þ and Pat-QKIþ / PB-derived monocytes
and macrophages. Primers were designed to target constitutive ﬂanking exons. PCR product size for exon inclusion (top) and exclusion (bottom) variants
are provided (left). (d) Phase-contrast and ﬂuorescence-microscopy photographs (scale bar, 50mm) of primary human, PB macrophages of healthy
controls that have been treated with FAM-labelled GapmeRs, to reduce QKI expression. (e) Quantitative RT–PCR (qRT–PCR) of QKI mRNA isoform
expression in GapmeR-treated macrophages (n¼ 3). Data expressed as mean±s.e.m.; Student’s t-test, with **Po0.01. (f) PCR validation of alternatively
spliced cassette exons in GapmeR-treated PB-derived macrophages. Primers were designed to target constitutive ﬂanking exons. PCR product size for exon
inclusion (top) and exclusion (bottom) variants are provided (left). A representative illustration is shown of an n¼ 3 donors. Data expressed as
mean±s.e.m.; Student’s t-test, with **Po0.01 and #P¼0.08.
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associated with changes in exon inclusion (for example, ADD3),
alternative 50-splice sites (PARP2), alternative 30-splice sites
(M6PR) and intron retention (for example, BICD2), thereby
expanding the detection of veritable QKI-regulated events beyond
cassette exons (splice event ‘se’ location deﬁned by brackets).
Importantly, strong correlations were observed between QKI
expression levels and the magnitude of the splicing event, be it
between the patient and sibling control, or between monocytes
and macrophages (Fig. 4b).
Finally, we validated several alternatively spliced cassette exons,
including events in ADD3, LAIR1 and UTRN by reverse
transcriptase–PCR (RT–PCR), using primers in ﬂanking exons
(Fig. 4c). Collectively, our RNA-seq data analysis of this unique
QKI haploinsufﬁcient individual strongly suggested a direct role
for QKI in regulating alternative splicing events that could
inﬂuence monocyte to macrophage differentiation.
To extend results obtained with the QKI haploinsufﬁcient
patient, we abrogated QKI expression in naive primary human
monocytes harvested from freshly drawn venous blood of healthy
controls. We designed GapmeR antisense oligonucleotides that
either targeted QKI for degradation (QKI-Gap), or are scrambled
as a control (Scr-Gap), coupled with a 50-FAM label to track
their cellular uptake. The QKI-Gap and Scr-Gap compounds
were administered to the freshly isolated monocytes, concomitant
with GM-CSF for 96 h, to drive the differentiation to
pro-inﬂammatory macrophages. In contrast to our attempts
to reduce QKI mRNA levels using other well-established
approaches, we observed virtually no signs of cytotoxicity or
apoptosis following GapmeR treatment. Furthermore, the
treatment did not hamper the capacity of monocytes to
differentiate into macrophages (Fig. 4d top), while uptake
efﬁciency approached 100% (based on FAMþ cells; Fig. 4d
bottom). After 96 h, we harvested RNA from the QKI-Gap- and
Scr-Gap-treated macrophages, which yielded a minimal reduction
in QKI-5 mRNA levels but remarkable reductions in QKI-6 and
QKI-7 mRNAs (Fig. 4e). Albeit that the GapmeR-mediated
reduction in QKI expression in primary human macrophages was
not as striking as that observed in the QKI haploinsufﬁcient
patient, it nonetheless enabled us to visualize and validate signi-
ﬁcant changes in several of the aforementioned QKI-mediated
alternative splicing events, such as ADD3 and FcgR-IIb (FCGR2B)
(Fig. 4f; n¼ 3 donors). It should be noted that the inability to
remarkably reduce the expression of the nuclear QKI isoform,
namely QKI-5, could be responsible for the discrepancy between
the striking shift in splicing observed in the QKI haploinsufﬁcinet
patient as compared with the GapmeR-mediated abrogation
of QKI expression. Taken together, these studies clearly
pinpoint QKI as a regulator of pre-mRNA splicing during
monocyte-to-macrophage differentiation and implicate QKI gene
dosage as a determinant of splicing event magnitude.
QKI regulates transcript abundance in THP-1 cells. To provide
further support for a regulatory role for QKI during monocyte-to-
macrophage differentiation, we tested whether QKI could
similarly modulate transcript abundance and pre-mRNA splicing
in a well-established monocyte cell line, namely THP-1 cells.
Similar to GM-CSF-induced differentiation of PB monocytes into
macrophages, the 12,13-phorbol myristyl acetate (PMA)-induced
transition of THP-1 ‘monocytes’ to ‘macrophages’ was associated
with the following: (1) signiﬁcantly increased expression of all
QKI mRNA transcripts (Fig. 5a); (2) barely detectable levels of
QKI protein in THP-1 ‘monocytes’ (Fig. 5b and Supplementary
Fig. 4a); and (3) signiﬁcantly increased expression of QKI protein
during THP-1 ‘monocyte’ to ‘macrophage’ differentiation
(Fig. 5b,c). Next, we stably transduced THP-1 ‘monocytes’ with
either short-hairpin RNA (shRNA) targeting QKI (sh-QKI)
to speciﬁcally deplete QKI or with a non-targeting shRNA
control (sh-Cont) (Supplementary Fig. 4b). Similar to GM-CSF-
stimulated Pat-QKIþ / versus Sib-QKIþ /þ monocytes,
sh-QKI THP-1 ‘monocytes’ displayed an inability to adopt the
‘macrophage’ morphology following stimulation with PMA as
compared with sh-Cont THP-1 ‘monocytes’ (Supplementary
Fig. 4c arrows). We subsequently determined mRNA levels using
an exon junction microarray44 analysing RNA isolated from
unstimulated and 3 days PMA-stimulated THP-1 sh-Cont and
sh-QKI ’monocytes’ and ‘macrophages’ (Supplementary
Data 5). Next, as shown in Fig. 5d, we assessed the expression
proﬁle of established monocyte differentiation genes (for
example, CD14m, CXCL8m, CSF1Rm, ApoEm, CX3CR1k,
CCR2k and CCL22k). Similar to QKI haploinsufﬁcient
macrophages, several markers in sh-QKI THP-1 ‘macrophages’
displayed an anti-atherogenic phenotypic shift (IL6k, IL23ak,
CD16Ak, CD16Bk, ApoEk and IL10m) as compared with
sh-Cont THP-1 ‘macrophages’ (Fig. 5d).
At the genome-wide level, the reduction of QKI signiﬁcantly
altered the abundance of 359 and 573 mRNAs in THP-1
‘monocytes’ and ‘macrophages’, respectively (Fig. 5e, Supple-
mentary Data 5 and Supplementary Fig. 3 bottom). Of these
differentially expressed mRNAs, 56 and 128 were computationally
predicted QKI targets based on the presence of a QRE in the
mature mRNA (Fig. 5e intersect). The most differentially expressed
transcripts harbouring a QRE are denoted in Fig. 5f. The
expression levels of mRNAs targeted by QKI in THP-1 ‘mono-
cytes’ and ‘macrophages’ are depicted in Fig. 5g (blue dots) and
Fig. 5h (blue lines), relative to those not directly affected by
Figure 5 | QKI inﬂuences mRNA transcript abundance during differentiation of THP-1 monocyte-like cells to THP-1 macrophage-like cells. (a) mRNA
expression of the QKI isoforms as compared with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in THP-1 ‘monocytes’ and 8 days differentiated
THP-1 ‘macrophages’ (biological n¼ 3). Data expressed as mean±s.e.m.; Student’s t-test; *Po0.05 and **Po0.01. (b) Western blot analysis of whole-cell
lysates of THP-1 ‘monocytes’ and THP-1 ‘macrophages’. (c) Western blot quantiﬁcation of QKI protein isoforms, normalized to b-actin in THP-1 ‘monocytes’
and THP-1 ‘macrophages’ (n¼ 3). Data expressed as mean±s.e.m.; Student’s t-test; **Po0.01. (d) Hierarchical clustering (Euclidean algorithm) of key
monocyte differentiation genes depicting changes in microarray-derived mRNA abundance THP-1 ‘monocytes’ (left two lanes) and THP-1 ‘macrophages’
(right two lanes), where dark blue¼ low expression, whereas light blue¼ high expression (* and/or # beside gene name is indicative of a signiﬁcantZ1.5-
fold change in expression in monocytes or macrophages, respectively). (e) Venn diagrams depicting the number of microarray-derived differentially
expressed genes (minimally ±1.5-fold; sh-QKI/sh-Cont expression, q-valuer0.05) for unstimulated THP-1 ‘monocytes’ (left Venn diagram) and THP-1
‘macrophages’ (right Venn diagram). (f) The most signiﬁcantly differentially expressed genes harbouring a QRE are shown. (g) Genome-wide scatterplot of
mRNA abundance in THP-1 ‘monocytes’ (left scatterplot) and THP-1 ‘macrophages’ (right scatterplot); y axis: Log10 probe intensity versus the x axis:
log2FC: sh-QKI average probe intensity/sh-Cont average probe intensity. Blue dots indicate QRE-containing transcripts that are minimally ±1.5 fold
differentially expressed (qr0.05). Grey dots do not fulﬁll these criteria. (h) CDF (y axis) for QKI target (QRE containing: blue line) and non-target (non-
QRE containing: cyan line) mRNAs (x axis: log2FC) in THP-1 ‘monocytes’ (left plot) and THP-1 ‘macrophages’ (right plot). Left shift indicates lower
expression of QKI target genes in the sh-QKI samples, whereas a right shift is indicative of higher expression of QKI targets in the sh-QKI samples.
Distributions were compared using a Wilcoxon rank-sum test.
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changes in QKI levels (Fig. 5g grey dots and Fig. 5h cyan lines).
Consistent with our analyses in PB monocytes, putative direct QKI
target mRNAs were mostly reduced on a targeted QKI reduction in
THP-1 ‘monocytes’ (Fig. 5h, left plot), although a shift towards
increased target mRNA abundance in THP-1 ‘macrophages’ was
not observed (Fig. 5h, right plot).
QKI modiﬁes pre-mRNA splicing patterns in THP-1 cells.
Having identiﬁed that QKI haploinsufﬁciency generates
pre-mRNA splicing events that probably have an impact on
monocyte and macrophage biology, we also analysed RNA
isolated from sh-Cont and sh-QKI THP-1 ‘monocytes’ and
‘macrophages’ for alternative splicing events using the exon
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junction microarray platform44. This highly sensitive
technology uses probes that are designed speciﬁcally to detect
both constitutive exon–exon junctions and alternative exon–exon
junctions, enabling one to quantify inclusion ratios for alternative
splicing events. These studies uncovered 571 and 629
differentially regulated alternative splicing events in THP-1
‘monocytes’ and ‘macrophages’, respectively, including
numerous cassette exons, alternative 50- and 30-splice sites, and
retained introns (Fig. 6a and Supplementary Data 6; n¼ 3).
Detected splicing events are illustrated in Fig. 6b, where the
skip and include intensities (y axis and x axis, respectively)
of transcript-speciﬁc hybridization probes directed to either
the constitutive or alternatively spliced exons are plotted.
The separation score, obtained by determining slope
differences, indicates the magnitude of the splicing event.
Similar to the motif enrichment analyses performed for the
RNA-seq of PB monocytes and macrophages, these studies
conﬁrmed that exon skipping frequency was signiﬁcantly
correlated with alternative exons that had an ACUAA motif in
the upstream intron (Fig. 6c left panels and Supplementary Data
4). In contrast to the subtle enrichment of inclusion frequency
observed in Pat-QKIþ / and Sib-QKIþ /þ monocytes and
macrophages (Fig. 3a right panels), exon inclusion frequency in
THP-1 ‘monocytes’ and ‘macrophages’ was clearly associated with
the presence of ACUAA motifs in the downstream intron (Fig. 6c
and Supplementary Data 4).
Finally, alternative cassette exons in THP-1 ‘monocytes’ and
‘macrophages’ were PCR validated (Fig. 6d). Importantly, we also
selected several top splicing events from THP-1 ‘monocytes’ and
‘macrophages’ (Supplementary Data 6), and validated these in
RNA harvested from wt and qkv mice, including REPS1, PTPRO
and FGFR1OP2 (Fig. 6e).
QKI targets monocyte activation and differentiation pathways.
We subsequently determined how QKI-induced changes in
mRNA transcript abundance could have an impact on Gene
Ontology (GO) enrichment of coordinately regulated pathways
during monocyte-to-macrophage differentiation. As shown in
Table 1 and Supplementary Data 7, these GO analyses point
towards a central regulatory role for QKI in immune responses to
injury, processes that play a critical role in the onset and
development of atherosclerosis and other inﬂammation-based
diseases. In both monocytes and macrophages, changes in QKI
expression clearly had an impact on Liver X Receptor (LXR)/
Retinoid X Receptor (RXR) activation and Peroxisome
Proliferator-Activated Receptor (PPAR) activation and signalling,
implicating a key role for QKI in regulating cholesterol
biosynthesis and metabolism. Furthermore, a reduction in QKI
expression also appeared to inﬂuence T-cell and Toll-like receptor
signalling, biological processes that play prominent roles in the
rapid resolution of infection, while in chronic settings exacerbate
inﬂammatory conditions. Finally, the gene enrichment analysis
suggested that posttranscriptional processing of factors driving
the recruitment, adhesion and diapedesis of immune cells were
affected by changes in QKI expression.
QKI facilitates monocyte adhesion and migration. Our
experimentally determined changes in (pre)-mRNA splicing and
expression, as well as bioinformatically predicted changes in
biological processes, prompted us to evaluate whether these
QKI-induced posttranscriptional modiﬁcations could affect
monocyte and macrophage function. To test this, we ﬁrst assessed
whether cell survival is affected by a reduction of QKI expression
in THP-1 ‘monocytes’. Importantly, the cumulative population
doublings and apoptotic rates were not affected by decreased
QKI levels (Fig. 7a,b). Next, we assessed cell adhesion to glass
coverslips treated with effector molecules (collagen and activated
platelets) in the presence of ﬂuid shear stress, an experimental
design that mimics the response of monocytes to endothelial
denudation in the vessel45. Live-cell imaging clearly showed that
the shRNA-mediated depletion of QKI in THP-1 ‘monocytes’
reduced cellular adhesion under ﬂow conditions, as evidenced by
their continued rolling along the substrate and inability to ﬁrmly
attach (Fig. 7c and Supplementary Movies 1 and 2). This ﬁrm
adhesion of monocytes is aided by the activation of b1-integrins
on the cell surface that mediate high-afﬁnity interactions with the
extracellular matrix at sites of injury36. We tested whether
QKI depletion had an impact on b1-integrin function by
incubating sh-Cont and sh-QKI THP-1 ‘monocytes’ with an
antibody (TS2/16) that forces b1-integrins into the activated,
adhesive conformation37. Interestingly, the abrogation of QKI did
not affect monocyte adhesion properties in this setting (Fig. 7d),
indicating that proper integrin expression and functionality is not
dependent on QKI.
We subsequently tested whether QKI expression levels could
have an impact on monocyte migration in vitro by seeding
sh-QKI or sh-Cont THP-1 ‘monocytes’ into transwell migration
chambers and assessed their ability to migrate towards the
chemoattractant formyl-methionyl-leucyl-phenylalanine (fMLP).
Indeed, depletion of QKI in monocytes inhibited migration
(Fig. 7e). This ﬁnding prompted us to similarly assess the capacity
of Pat-QKIþ / and Sib-QKIþ /þ monocytes freshly isolated
from venous blood to migrate to macrophage chemoattractant
protein 1, a physiologic recruiter of monocytes at sites of vascular
injury. These studies revealed a signiﬁcant reduction in transwell
migration for Pat-QKIþ / monocytes (Fig. 7e), validating our
ﬁndings in THP-1 ‘monocytes’, and provided evidence that QKI
inﬂuences monocyte adhesion and migration in inﬂammatory
settings.
QKI drives foam cell formation. As QKI expression remarkably
increased during monocyte-tomacrophage differentiation
(Fig. 2c–f) and our aforementioned GO analysis revealed a strong
association for changes in QKI expression and lipid metabolism
(Fig. 7a), we tested whether a reduction in QKI expression
inﬂuences the handling of lipids. For this, we ﬁrst assessed the
mRNA expression levels of a subset of established lipid-related
genes in monocytes and macrophages derived from WT and qkv
mice. As shown in Fig. 8a, monocytes from qkv mice are
characterized by signiﬁcant reductions in NR1H3 (known as
LXRa) and PPARG (PPARg) expression, as well as cholesterol
uptake (CD36 and LDLR) and efﬂux (ABCG1) receptors, as
compared with WT monocytes. These effects were diminished on
conversion to macrophages (Fig. 8a).
We subsequently assessed the expression levels of these lipid
metabolism/homeostasis genes in human PB-derived monocytes
and macrophages (Fig. 8b and Supplementary Fig. 5). Similar to
qkv monocytes, Pat-QKIþ / monocytes were characterized by
decreased NR1H3 and PPARG expression, as well as LDLR and
SCARB1 (Fig. 8b). In contrast to qkv monocytes, ABCG1
expression was potently increased. Similar to qkv macrophages,
this differential gene expression proﬁle appeared to normalize in
Pat-QKIþ / macrophages as compared with Sib-QKIþ /þ
macrophages (Fig. 8b). Moreover, in primary human macro-
phages where GapmeR-mediated knockdown of QKI was
realized, we observed signiﬁcant increases in MYLIP/IDOL and
ABCG1 expression, whereas CD36 displayed a trend towards
decreased expression (Supplementary Fig. 5).
Having identiﬁed that changes in QKI expression levels
had an impact on lipid-associated gene expression, we
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Figure 6 | QKI expression levels inﬂuence pre-mRNA splicing during THP-1-based monocyte-like to macrophage-like cell differentiation.
(a) Schematic depicting detectable alternative splicing events with the splicing-sensitive microarray platform and number of inclusion (incl.; top lines) or
exclusion (excl.; bottom lines) events observed in unstimulated THP-1 ‘monocytes’ (left) and 3-day PMA-stimulated THP-1 ‘macrophages’ (n¼ 3, qr0.05).
(b) Scatterplots of skip (y axis) and include (x axis) probe set intensity for selected alternative splicing events in sh-Cont (blue boxes) versus sh-QKI
(orange circles) in unstimulated and 3 days PMA-stimulated THP-1 ‘monocytes’ and ‘macrophages’, respectively. Regression coefﬁcients (constrained to
pass the origin) are depicted as solid lines. The log2 difference in the slopes (termed separation score; ss) are provided to the right of the plots for each
event, with for example, an ss of  1.72, indicating a 3.3-fold more inclusion of ADD3 exon 13 in sh-QKI versus sh-Cont THP-1 ‘monocytes’. Full event
details are provided in Supplementary Data 6. CE, cassette exon; Alt 50 or 30, alternative 50 or 30 splice site; RI, retained intron. (c) SpliceTrap assessment of
average proximal ACUAA RNA motif enrichment in 50 bp windows upstream and downstream of alternatively spliced cassette exons as compared with a
background set of exons (grey circles). The relationship between the frequency of exon exclusion (blue triangles) or exon inclusion (red squares) and
ACUAA RNA motif enrichment are depicted. (d) PCR validation of alternatively spliced cassette exons in sh-Cont and sh-QKI THP-1 ‘monocytes’ and
‘macrophages’. Primers were designed to target constitutive ﬂanking exons. PCR product size for exon inclusion (top) and exclusion (bottom) variants are
provided (left). All experiments depict biological n¼ 3. (e) PCR validation of three splicing events in wt and qkv mouse-derived primary monocytes and 7
days M-CSF-stimulated macrophages. PCR product size for exon inclusion (top) and exclusion (bottom) variants are provided (left). Depicted is a
representative PCR for at least a biological nZ3.
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investigated whether lipid loading affected QKI expression
levels. Indeed, treatment with either acetylated low-density
lipoprotein (acLDL) or b-very low-density lipoprotein
(b-VLDL) led to signiﬁcant increases in QKI-5 mRNA
levels, while QKI-6 and QKI-7 levels also increased, albeit not
signiﬁcantly (Fig. 8c). In contrast to primary monocytes and
macrophages, THP-1 ‘monocytes’ did not display signi-
ﬁcant changes in lipid metabolism gene expression.
However, as shown in Fig. 8d, treatment with modiﬁed LDL
increased expression of cholesterol uptake genes (CD36 and
VLDLR), along with signiﬁcant increases in cholesterol efﬂux
genes (ABCA1 and ABCG1). Taken together, these studies
suggested that changes in QKI expression could have an impact
on the net balance of genes that control lipid metabolism and
homeostasis.
Finally, we tested whether these QKI-mediated changes in
lipid-associated gene expression could translate into conse-
quences for lipid uptake and foam cell formation, a phenomenon
tightly associated with pro-inﬂammatory macrophage function7.
As shown in Fig. 8e, the impact of decreased QKI expression on
foam cell formation on loading with b-VLDL was clear, as
sh-QKI THP-1 ‘macrophages’ displayed less extensive lipid
staining as compared with sh-Cont THP-1 ‘macrophages’
(Fig. 8e). Similarly, in Pat-QKIþ / macrophages we observed
signiﬁcantly less lipid staining after b-VLDL treatment (Fig. 8f).
Even more striking was the potent decrease in oxidized LDL
(oxLDL) loading, an atherosclerosis-relevant antigen, in
Pat-QKIþ / macrophages (Fig. 8f). Collectively, these studies
strongly suggested that the posttranscriptional processing of
(pre-) mRNA transcripts by QKI is essential for the physiologic
functioning of monocytes and macrophages in disease settings
such as atherosclerosis.
Discussion
Genes involved in regulating the transition of monocytes into
pro-inﬂammatory macrophages serve as excellent therapeutic
targets for limiting the progression of inﬂammation-driven
diseases such as rheumatoid arthritis and atherosclerosis3,6. Our
data indicate that alongside wide-ranging changes in gene
expression, the differentiation of monocytes to macrophages
requires extensive alternative splicing of pre-mRNA species and
Table 1 | IPA assessment of pre-deﬁned canonical pathways affected by changes in QKI expression.
Monocytes Macrophages
THP-1 sh-QKI
versus sh-Cont
THP-1 sh-QKI
versus sh-Cont
Affected canonical
pathway
 Log
(P-value)
Affected genes Affected canonical
pathway
 Log
(P-value)
Affected genes
Atherosclerosis
signalling
9.2 CXCL8, APOE, ICAM1, PDGFA, PLA2,
G4C, CCR2, F3, LYZ, CCL2, ORM1,
APOC1, IL1B, ORM2, PDGFD, TNF
Superpathway of
cholesterol biosynthesis
10.6 FDPS, PDFT1, EBP, DHCR7, ACAT2, IDI1,
HSD17B7, MSMO1, HMGCS1, CYP51A1
Superpathway of
cholesterol biosynthesis
8.2 MVD, FDPS, CHCR7, ACAT2,
HSD17B7, MSMO1,
HMGCS1,CYP51A1
Cholesterol biosynthesis I,
II, and III
8.1 FDFT1, EBP, DHCR7, DHCR24, HSD17B7,
MSMO1, CYP51A1
LXR/RXR activation 7.4 SCD, APOE, LYZ, ORM1, CCL2,
APOC1, IL1B, ORM2, CD14, PTGS2,
IL1RAP, TNF, CYP51A1
Superpathway of
gernanylgeranylphosphate
Biosynthesis I
4.4 FDPS, ACAT2, IDI1, FNTB, HMGCS1
Hepatic ﬁbrosis/hepatic
stellate cell activation
6.1 CXCL8, APOE, ICAM1, PDGFA, PLA2,
G4C, CCR2, F3, LYZ, CCL2, ORM1,
APOC1, IL1B, ORM2, PDGFD, TNF
LXR/RXR activation 4.4 SCD, FDFT1, LYZ, IL1A, LDLR, IL36RN, NR1H3,
IL6, CLU, CYP51A1, IL36B, AGT
PPAR signalling 5.8 PPARG, JUN, PPARD, PDGFA, MRAS,
IL1B, PTGS2,PDGFD, TNF, IL1RAP
Altered T-cell and B-cell
signalling in rheumatoid
arthritis
4.3 IL1A, CSF1, IL36RN, TLR6, TLR8, TLR7, IL6,
CSF2, IL36B, IL17A
RNA-seq Pat-QKI
versus Sib-QKI
RNA-seq Pat-QKI
versus Sib-QKI
Affected canonical
pathway
 Log
(P-value)
Affected genes Affected canonical
pathway
 Log
(P-value)
Affected genes
T-cell receptor signalling 8.9 CD247, PTPN7, CAMK4, PRKCQ,
CD3E, PLCG1, CD8A, CD3D,CD8B,
CD28, CD3G, LCK, TXK, ZAP70, ITK
Granulocyte adhesion and
diapedesis
4.9 CXCL8, IL1A, HRH2, MMP7, SDC1, PPBP,
ITGA6, RDX, CCL24, CCL17, MMP2, CCL22,
C5, FPR1, CCL13, ICAM2, IL1RN, MMP19,
ITGA4
CCR5 signalling in
macrophages
7.8 CD247, CD3G, CCR5, CAMK4,
PRKCQ, CCL4, CD3E, PLCG2, PLCG1,
CCL3, CD3D, GNG10
Agranulocyte adhesion
and diapedesis
4 CXCL8, MMP7, IL1A, PPBP, ITGA6, RDX,
CCL24, CCL17, MMP2, CCL22, C5, MYL9,
CCL13, ICAM2, IL1RN, PODXL, MMP19,
ITGA4
Role of NFAT in
regulation of the immune
response
7 CD247, CAMK4, PRKCQ, CD3E,
GCER1A, PLCG1, CD3D, GNG10,
CD28, CD3G, LCK, GNAT1, PLCG2,
ZAP70, FCGR3A/GCGR3B, FCGR1B,
ITK
Toll-like receptor signalling 3 MAP2K6, IL1A, TICAM2, IL1RN, TLR7,
MAPK13, TLR3, IRAK2, TRAF1
EIF2 signalling 5.8 RPL24, RPL36A, RPS3A, RPS27,
RPL17, RPS18, RPS10, RPL39, RPL12,
RPL7A, RPL7, RPL9, RPS28, RPL23A,
RPL39L, RPSA
Cysteine biosynthesis/
homocysteine degradation
2.9 CBS/CBSL, CTH
iCOS-iCOSL signalling in
T-helper cells
5.7 CD247, CD3G, CD28, LCK, CAMK4,
PRKCQ, CD3E, ZAP70, PLCG1, CD3D,
ICOSLG/LOC102723996, ITK
Axonal guidance signalling 2.9 SLIT3, ERAP2, MMP7, SLIT1, PDGFA,
SEMA6A, BCAR1, TUBB2B, EPHB1, TUBA8,
MYSM1, PRKAR1B, GNB1L, WNT5B, ITGA4,
SEMA3G, PAK4, ADAM15, TUBA4A, MMP2,
KEL, MYL9, FZD4, ADAM12, SEMA4G,
SEMA7A, FZD7
IPA, Ingenuity Pathway Analysis; QKI, Quaking.
The top ﬁve affected canonical pathways are shown, along with their respective –log(P-value) and the genes that are affected within the particular pathway. Full IPA output is provided in Supplementary
Data 7.
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pinpoint QKI as a novel posttranscriptional regulator of both of
these processes (Fig. 9).
Expression of the transcription factor PU.1 is associated with
the activation of gene expression proﬁles that drive the
differentiation of CD34þ haematopoietic progenitor cells
towards a myeloid fate, including monocytes and macro-
phages46,47. Recent work by Pham et al.48 identiﬁed that the
binding of PU.1 appears to be enhanced by cooperativity with
neighbouring transcription factor binding sites, such as KLF4.
Importantly, PU.1 induces the expression of critical monocyte
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Figure 7 | QKI expression levels have an impact on monocyte adhesion as well as migration and differentiation. (a) Cumulative population doublings (y
axis: CPDs) were counted to assess the effect of QKI reduction on cellular proliferation over time (x axis: days). Population growth curves were compared
using linear regression analysis.(b) Quantiﬁcation of cellular apoptosis, where annexin Vþ and propidium iodideþ cells were categorized as apoptotic, as
determined by FACS analysis. (c) Quantiﬁcation of sh-Cont and sh-QKI THP-1 ‘monocyte’ adhesion to collagen matrix pretreated with platelet-rich plasma
under ﬂow, mimicking in-vivo endothelial denudation. Direction of ﬂow is indicated below the photomicrographs (n¼ 3). Data expressed as mean±s.e.m.;
Student’s t-test; *Po0.05. Scale bar, 100mm. (Also see Supplementary Movies 1 and 2). (d) Assessment of integrin-mediated adhesion. Quantiﬁcation of
adhesion to collagen for untreated, PMA- or TS2/16-treated sh-Cont and sh-QKI THP-1 ‘monocytes’ are plotted. TS2/16 is an antibody that turns all
b1-integrins in the high-afﬁnity conformation, inducing cellular adhesion. (e) Quantiﬁcation of cellular transwell migration towards either fMLP (for THP-1
‘monocytes’) or macrophage chemoattractant protein 1 (MCP-1; for PB monocytes from either sibling or patient (n¼4 technical replicates). Data expressed
as mean±s.e.m.; Student’s t-test; *Po0.05 and **Po0.01.
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transcription factors, including KLF4 (ref. 49). Of note, KLF4 has
been demonstrated to bind to the QKI promoter region of
VSMCs, which is GC rich50. Furthermore, chromatin
immunoprecipitation sequencing data derived from HL-60 cells
embedded in the UCSC Encode browser revealed two
experimentally determined PU.1-binding sites in the QKI
promoter51 (Supplementary Fig. 6). Collectively, these ﬁndings
suggest that PU.1, potentially in concert with KLF4, could be
responsible for driving QKI expression during monocyte-to-
macrophage differentiation.
Our ﬁndings also suggest that the abundant expression of
QKI mRNAs in naive monocytes could serve to prime these
cells with the capacity to rapidly respond to pro-inﬂammatory
triggers at sites of injury. Although we did not assess
the translational kinetics of QKI mRNA into protein, our
investigation of monocyte activation, adhesion and differentiation
strongly suggests that the determination of pre-mRNA fate by
QKI critically has an impact on the capacity of the monocyte to
aid in response to vascular injury. To date, the genome-wide
(alternative) splicing patterns during monocyte-to-macrophage
differentiation had not been described. However, the
consequences of many splicing events herein described, such as
g-adducin (ADD3), FCGR2B and VLDLR are unknown.
However, given that phosphorylation of the g-adducin
C terminus triggers dissociation from spectrin and cortical actin
loss52, it is plausible that the QKI-mediated exclusion of a 13
amino acid coding exon proximal to this region could have an
impact on cytoskeletal dynamics in monocytes and macrophages.
Furthermore, alternative splicing of exon 6 in FCGR2B could
potentially have an impact on the inhibitory role of this protein in
monocyte- and macrophage-mediated phagocytosis at sites of
vascular injury53. Therapeutic strategies tailored to target such
splicing events in monocytes could potentially deter their
conversion to disease-accelerating macrophages.
The expanding repertoire of RNA species have led to the
emergence of RNA-based therapeutics as a novel means of
treating both rare and common diseases, such as muscular
dystrophy and cancer, respectively54,55. This is based on extensive
efforts geared towards identifying how changes in coding
(alternative splicing) and non-coding RNAs (miRNA and long-
non-coding RNA) have an impact on cellular pathophysiology56.
Importantly, the fate of these coding and non-coding RNAs
at the cellular level are determined primarily by the more than
500 RBPs that regulate eukaryotic cell biology32. Recently, the
RNA motifs to which a signiﬁcant portion of these RBPs bind has
been characterized32, enabling the systematic identiﬁcation of
RNA targets for a given RBP within cells, including QKI29–32.
Our genome-wide evaluation of posttranscriptional events
mediated by QKI implicate both direct and indirect
posttranscriptional roles for this protein, where the absence
of ACUAA motifs or QREs could nonetheless involve QKI,
potentially by tethering to other RBPs, or through QKI-mediated
changes in the expression of other RBPs57. Moreover, in spite
of the presence of QREs within target mRNAs, monocytes
and macrophages probably express a large variety of RBPs
that compete with QKI for access to either identical or similar
motifs with varying afﬁnities within a short stretch of RNA
nucleotides19, which could preclude the observation of a
posttranscriptional event.
In conclusion, we have identiﬁed QKI as a critical posttran-
scriptional regulator of pre-mRNA splicing and transcript
abundance in monocytes and macrophages. We propose that
the RBP-induced reprogramming of the posttranscriptional
landscape could generate novel targets for the effective
attenuation of inﬂammatory diseases.
Note added in proof: After the acceptance of our paper, we were
informed by Dehghan et al.58 of the CHARGE Consortium’s
identiﬁcation that single nucleotide polymorphisms proximal to
QKI signiﬁcantly associated with myocardial infarction and
coronary heart disease risk.
Methods
Human immunohistochemistry studies. Early lesions are deﬁned as fatty streaks
or PIT, whereas advanced plaques consist of both FCA and IPH (ﬁbroatheroma with
early-stage or late-stage necrotic core). Scoring of plaque stage, based on character-
istics such as thin cap ﬁbroatheroma (vulnerable or ruptured plaques), vasculariza-
tion, IPH and/or thrombi/ﬁbrin deposits, were scored by a trained pathologist.
Parafﬁn tissue sections from human carotid arteries were deparafﬁnized and
rehydrated. After pre-treatment with TE buffer (pH 9 for QKI-5 and QKI-7) or
citrate buffer (pH 6 for QKI 6) for antigen retrieval, sections were incubated
overnight at 4 C with primary mouse-anti-human pan-QKI (10mgml 1, clone
N147/6; UC Davis/NIH NeuroMab Facility, Davis, CA, USA), mouse anti-human
QKI-5 (10 mgml 1, clone N195A/16; NeuroMab/Antibodies, Inc.); mouse
anti-human QKI-6 (10 mgml 1, clone N182/17; NeuroMab/Antibodies Inc.) or
mouse anti-human QKI-7 (10 mgml 1, clone N183/15; NeuroMab/Antibodies
Inc.) diluted in Tris-buffered saline containing 1% BSA and 0.1% Tween 20.
Subsequently, sections were washed in Tris-buffered saline and incubated with a
secondary biotinylated sheep-anti-mouse antibody (GE Healthcare, Eindhoven,
The Netherlands). Next, the sections were incubated with streptavidin
ABC-alkaline phosphatase (Vector Laboratories, Peterborough, UK) and colour
was developed using the Vector Red staining kit (Vector Laboratories), followed by
haematoxylin counterstaining. No primary antibody was used for the negative
control. QKI/CD68 co-localization immunostaining was achieved using CD68
(Dako-KP1, DakoCytomation) and pan-QKI antibodies, with CD68 and QKI being
counterstained with Vector Blue and Vector Red, respectively. For quantiﬁcation,
slides were analysed in a blinded manner using a Leica DM3000 light microscope
(Leica Microsystems) coupled to computerized morphometry (Leica Qwin 3.5.1).
BM transplantation. Male LDLR / mice were housed in sterile ﬁlter-top cages
and fed a chow diet (Special Diet Services, Witham, Essex, UK). Drinking water
was infused with antibiotics (83mg l 1 ciproﬂoxacin and 67mg l 1 polymyxin
B sulfate) and 6.5 g l 1 sugar and was provided ad libitum. BM transplantation
studies were performed as previously described with minor modiﬁcations59.
Brieﬂy, to induce BM aplasia, 10- to 12-week-old recipient mice were exposed to
a single dose of 9 Gy (0.19 Gymin 1, 200 kV, 4mA) total body irradiation,
using an Andrex Smart 225 Ro¨ntgen source (YXLON International, Copenhagen,
Denmark) with a 6-mm aluminium ﬁlter, 1 day before transplantation. After
24 h, BM cell suspensions were prepared by ﬂushing the femurs ofB12-week-old
qkv mice or age-matched LM controls (C57/Bl6-J background; Jackson
Laboratories, Bar Harbor, USA) with PBS, after which 5 106 cells were
injected into the tail vein of recipient mice. After 8 weeks of recovery, the
Figure 8 | QKI regulates the expression of atherosclerosis-related mRNAs and impairs foam cell formation. (a) Quantitative RT–PCR (qRT–PCR)
analysis of established atherosclerosis-related genes in wt of qkv-derived monocytes and macrophages. Gene expression in qkv samples are relative to
eitherWTmonocytes orWTmacrophages (nZ3). Data expressed as mean±s.e.m.; Student’s t-test; *Po0.05, **Po0.01. (b) RNA-seq-derived expression
values to illustrate the expression of established atherosclerosis-related genes in sibling or patient monocytes and macrophages. (c) qRT–PCR analysis of
QKI isoform mRNA expression in unstimulated THP-1 ‘macrophages’, or treated with b-VLDL or acLDL for 24 h. Data expressed as mean±s.e.m.; one-way
analysis of variance (ANOVA), Bonferroni’s post-hoc test; *Po0.05. (d) qRT–PCR analysis of well-known atherosclerosis-related genes in sh-cont or sh-QKI
THP-1 ‘macrophages’ that were either left untreated or treated with acLDL or b-VLDL to induce foam cell formation (n¼ 3). Data expressed as
mean±s.e.m.; Student’s t-test; *Po0.05 and **Po0.01. (e) Photomicrographs of an Oil-red-O staining to assess b-VLDL, acLDL uptake in either sh-Cont
or sh-QKI THP-1 ‘macrophages’. Scale bar, 100mm. Inset is a high-magniﬁcation image of lipid-droplet accumulation. Data expressed as mean±s.e.m.;
Student’s t-test; **Po0.01. (f) Photomicrographs of an Oil-red-O staining to assess b-VLDL, acLDL or oxidized LDL (oxLDL) uptake in either Sib-QKIþ /þ
(upper panels) or Pat-QKIþ / (lower panels) macrophages that were ﬁrst differentiated for 7 days with GM-CSF. Scale bar, 100mm. Inset is a
high-magniﬁcation image of lipid-droplet accumulation. Data expressed as mean±s.e.m.; Student’s t-test; *Po0.05 and **Po0.01.
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mice were placed on a Western-type diet, containing 0.25% cholesterol
and 15% cacao butter (Special Diet Services) for 8 weeks (n¼ 12 per group).
Immunohistochemical analysis and quantiﬁcation of the aortic root using
anti-Monocyte and Macrophage-2 (MOMA2) antibody (Sigma-Aldrich) for
MOMA2-positive cell area (expressed as a percentage of total plaque area),
VSMC content (smooth muscle a-actin-positive cells) and collagen (picosirius
red staining) was performed in a blinded manner. Haematologic chimerism of the
transplanted LDLR / mice was validated using the following primers: qk
forward primer 50-TGTGACTTGGGGACTGTCAA-30; qk reverse primer 50-
AAAGGGAAAATTTAGCAACAA-30 .
BM-derived WT and qkv monocytes were isolated using CD115þ antibody
coupled to magnetic beads (Miltenyi Biotech, Leiden, The Netherlands) and
differentiated for 7 days to macrophages using mouse recombinant M-CSF
(PeproTech, Hamburg, Germany) in RPMI 1640 medium (Gibco, Bleiswijk, The
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Netherlands) containing 10% FCS (Bodinco, Alkmaar, The Netherlands) and
0.01 mgml 1 glutamine, 50 units per ml penicillin and 50 mgml 1 streptomycin.
Lentiviral transduction of monocytes. Human THP-1 ‘monocytes’ (ATCC,
Manassas, VA, USA) were transduced with lentiviral particles encoding
either sh-QKI or sh-Cont (catalogue number: SHC202; MISSION library,
Sigma-Aldrich). Stable transductants were selected using 3 mgml 1 puromycin
(Sigma-Aldrich) for 72 h.
GapmeR design. A single-stranded RNA–DNA hybrid antisense
oligonucleotide (GapmeR) was designed to target exon 2 of QKI (Eurogentec,
Maastricht, The Netherlands), along with a scrambled GapmeR control. Both
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Figure 9 | Schematic depicting how QKI posttranscriptionally regulates monocyte to macrophage differentiation and atherosclerosis development.
QKI mRNA expression increases in intermediate monocytes, reaching a peak in the non-classical monocyte (middle). Monocytes adhere to the
endothelium at sites of tissue injury, leading to their activation and migration into the subendothelial space. This process requires QKI, as the targeted
ablation of QKI impaired monocyte adhesion and migration, and the evident transition in cellular phenotype requires extensive reprogramming of the
posttranscriptional landscape. On tissue entrance, the monocyte differentiates into a macrophage, a conversion that was associated with a potent increase
in QKI protein. This increase potentiates the interaction of QKI with (pre-)mRNA targets, enhancing splicing and target mRNA repression. The loss of QKI
in macrophages results in an inability to adopt the macrophage phenotype and a perturbation of lipid uptake and foam cell formation.
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the GapmeR and scrambled control were 22 nucleotides in length and consisted
of RNA (A,C,G,U) and DNA (dA, dC, dG, dT) in a 6-10-6 manner, with a
phosphorothioate backbone (*) and a 6-FAM label on the 50-end. GapmeR
sequences were as follows:50-A*C*A*U*G*U*dC*dT*dT*dT*dC*dC*dG*dT*
dA*dC*U*C*U*G*C*U-30 for the QKI-targeting GapmeR and 50-U*G*C*C*U*C*
dT*dC*dT*dC*dG*dT*dA*dC*dC *dG*U*A*U*U*U*A-30 for the scrambled
control.
Monocyte subpopulation analysis. Human monocytes were derived from healthy
donor buffy coats (Ethical Approval Number BTL 10.090) following Ficoll
density gradient centrifugation and isolated from the PB mononuclear cell fraction
using a negative selection cocktail to isolate unlabelled monocytes (StemCell
Technologies, Grenoble, France). Puriﬁed monocytes were subsequently incubated
with 1 mgml 1 CD14-FITC and 1 mgml 1 CD16-Pc5 (Beckman Coulter,
Woerden, The Netherlands) for 30min at 4 C and FACS sorted using a
FACSCalibur (BD Biosciences, Breda, The Netherlands). RNA was isolated from
the subpopulations using Trizol reagent (Thermo Fisher Scientiﬁc, Bleiswijk,
The Netherlands).
Monocyte and macrophage culture. Human monocytes were isolated from buffy
coats of healthy donors with an antibody to CD14, conjugated to magnetic beads to
allow for MACS sorting (Miltenyi Biotech). Cells were cultured in RPMI media
supplemented with 10% FCS and 0.01 mgml 1 glutamine at 37 C and 5% CO2.
Differentiation of primary CD14þ monocytes to pro-inﬂammatory macrophages
was achieved by stimulating with 5 ngml 1 GM-CSF (Thermo Fisher Scientiﬁc) or
5 ngml 1 M-CSF (Miltenyi Biotech). Human THP-1 ‘monocytes’ were cultured in
RPMI media supplemented with 10% FCS and 0.01 mgml 1 glutamine at 37 C
and 5% CO2, with differentiation into macrophages being induced by treating with
100 nM PMA60. TS/216 for integrin activation experiments was kindly provided by
Dr Arnoud Sonneberg, Netherlands Cancer Institute, Amsterdam, The
Netherlands. Foam-cell formation was assessed by treating sh-Cont and sh-QKI
THP-1 ‘macrophages’ or Sib-QKIþ /þ and Pat-QKIþ / macrophages for 24 h
with either 25 mgml 1 b-VLDL or 50 mgml 1 acLDL, or 10 mgml 1 oxLDL, after
which the cells were ﬁxed with 10% Formaﬁx, and Oil-Red-O stained and
haematoxylin counterstained. Oil-Red-O area per ﬁeld of view was divided by the
number of cells using ImageJ software.
In vitro perfusion assay. Glass coverslips were coated with type I collagen, after
which the system was perfused with platelet-rich plasma for 10min. Next, the
system was ﬂushed with ﬂow buffer (20mmol l 1 HEPES, 132mmol l 1 NaCl,
6mmol l KCl, 1mmol l 1 MgSO4, 1.2mmol l 1 KH2PO4, 5mmol l 1 glucose,
1.0mmol l 1 CaCl2 and 0.5% BSA) for 2min. Sh-Cont and sh-QKI THP-1
were resuspended in ﬂow buffer at a concentration of 4 106ml 1, after which
the cells were perfused over the substrate for 5min at 1 dyne cm 2. Cellular
adhesion was tracked visually using a Leica DMI5000 microscope. The ﬂow rate
was subsequently increased to 2 dynes cm2 for 2min, followed by the visual
assessment of ﬁrm adhesion of perfused monocytes for a duration of 3min, after
which photomicrographs of ten random ﬁelds of view in the ﬂuidic chamber were
taken and quantiﬁed.
Cellular migration assays. Transwell cellular migration studies of sh-Cont and
sh-QkI THP-1 ‘monocytes’ towards 1 nM N-formyl-methionyl-leucyl-phenylala-
nine (fMLP, Sigma-Aldrich) or 10 ngml 1 macrophage chemoattractant protein 1
(R&D Systems, Abingdon, UK) for human primary monocytes were performed
as previously described61. Brieﬂy, cell migration was assessed using Corning
Transwell polycarbonate membrane cell culture inserts (6.5mm transwell with
5.0 mm pore size, Sigma). The lower chamber was loaded with RPMI containing
0.25% BSA and desired chemoattractant. Wells containing no chemoattractant
were used as negative controls. Cells were loaded in the upper chamber of the
transwell inserts (105 cells) and incubated overnight at 37 C. The following day,
cell migration (adherent cells) was quantiﬁed by manual counting or ImageJ.
Gene expression microarrays. RNA was isolated from unstimulated sh-Cont and
sh-QkI THP-1 ‘monocytes’ (day 0), and from sh-Cont and sh-QkI THP-1 cells
stimulated with 100 nM PMA for 3 days using Trizol (Thermo Fisher Scientiﬁc)
and the RNeasy Mini Kit (Qiagen, Heidelberg, Germany) according to the
manufacturer’s instructions. RNA quantity and quality was measured using a
NanoDrop spectrophotometer (Nanodrop Technologies, Wesington, USA) and an
Agilent 2100 bioanalyser (Agilent Technologies, Santa Clara, USA). Samples
meeting a RNA integrity number critieria of 48 were used for further analysis.
Splicing microarrays. Microarray data is deposited in GEO under the accession
number GSE74887. Targets were prepared from three replicate cultures for each
sample. Complementary DNA synthesis and ampliﬁcation was performed using
the WT Expression Kit (Ambion, Bleiswijk, The Netherlands). Samples were
enzymatically fragmented and biotinylated using the WT Terminal Labeling Kit
(Affymetrix, Santa Clara, California, USA). Labelled target was hybridized to the
HJAY Chip (Affymetrix 540091). Chips were washed and scanned using the
Fluidics Station 450 and Affymetrix Gene ChIP Scanner 3000 7G (Affymetrix).
Data were analysed as previously described62. Brieﬂy, in the absence of mismatch
probes on these microarrays, probe intensities were ﬁrst used to construct an
empirical CDF, which was subsequently used to calculate an empirical P-value that
a particular probe’s intensity arose from the background of all probes. Probes were
stratiﬁed for GC content (thermodynamically favourable GC base pairing). For
each probe set, the median P-value of the set of individual probes in the probe set
was used as the P-value for that probe set. Before assessing for alternatively spliced
transcripts from a particular locus, we ﬁrst determined whether the gene was
expressed. Next, if the expression criteria was met, we determined whether RNA
containing two or more alternative splice junctions was detectable using the
isoform-speciﬁc probes. In situations where the probe sets for two or more
alternative isoforms were ‘present’ in any sample of the data, an alternative splicing
event was scored. For these events, the junction probe sets that hybridized to
individual isoforms were identiﬁed and the probes they contained were used for the
Kruskal–Wallis test. Next, we normalized individual probe intensities and grouped
the replicate values. Subsequently, using R software, the kruskal.test function
was used to test the hypothesis that the probe intensities come from identical
populations. If the resulting P-value was small enough, the null hypothesis was
rejected and the alternative hypothesis that the probes were differentially expressed
was accepted. To determine an appropriate value for the 0.01 signiﬁcance level,
12,740 Kruskal–Wallis tests on randomly selected probe sets were performed,
yielding an a-value that associated with the 1% quantile of randomly selected
probes (1.975486 10 3). To account for multiple testing, a Bonferroni-corrected
a-value of 1.975486 10 3/1.2740 104¼ 1.550617 10 7 was used as a
P-value cutoff for signiﬁcance. The Sepscore is log2 (Include/Skip ratio) of the
experimental sample over the reference sample. Exon inclusion generates a positive
Sepscore, whereas exon exclusion generates a negative Sepscore.
Word (5-mer) enrichment and positional mapping. Counts of all 5-mers
(ACUAA) in the selected region of an exon set are compared with their counts
from a background set of sequences using Fisher’s exact test, with multiple testing
correction. For motif mapping, we plotted the frequency of speciﬁc motifs in 50-
nucleotide windows slid along the intron sequences upstream and downstream of
each selected exon set with 5-nucleotide sampling intervals. At each interval, we
computed the average number of motifs in exons activated or repressed in
shRNA-treated cells, and background exons in the same experiment with no
splicing change. For the background set, we empirically estimated the 95%
conﬁdence interval of motif frequency (error bars). For peaks of consecutive points
outside the 95% interval, we applied the Mann–Whitney–Wilcoxon test to estimate
a P-value that the motif frequency at each point within the peak is greater than
background. As the points were not independent, we estimated a q-value for each
peak by ﬁnding the most signiﬁcant P-value for any point in the peak and applying
Bonferroni correction for the number of points within the peak. A second
Bonferroni correction controlled for the number of possible positions at which a
peak might occur, yielding the ﬁnal q-values. To explain further; the effect of QKI
depletion on every assessed exon was calculated from the RNA-seq or the splicing-
sensitive microarray: that is, whether a reduction in QKI causes inclusion or
exclusion from the ﬁnal mature mRNA transcript.
Next, the intronic regions around differentially spliced exons were analysed for
the presence of ACUAAmotifs (5-mers). By doing this for every alternatively spliced
exon, we could detect an enrichment of ACUAA motifs in the upstream introns of
the exons that were included in a ‘QKI-deﬁcient’ cell: QKI is not binding upstream;
thus, the exon is included, as measured by RNA-seq or splicing-sensitive microarray.
In contrast, we could detect an enrichment of ACUAA motifs in the
downstream introns of the exons that are included on QKI reduction. QKI binding
in the downstream intron would normally give inclusion, but now QKI cannot
bind downstream; thus, exclusion is now favoured as assessed by the RNA-seq or
splicing-sensitive microarray.
RNA-seq library preparation. RNA-seq data are deposited in GEO under the
accession number GSE74979. For each sample, the non-ribosomal fraction of
3 mg of total RNA was isolated using a Ribo-Zero rRNA removal Kit (Epicentre,
Madison, Wisconsin, USA). Ribo-Zero-treated RNAs were used to generate
barcoded cDNA libraries using the TruSeq RNA Sample Preparation kit (Illumina),
with the following additions. Size selections were performed before and after cDNA
ampliﬁcation on an E-gel Safe Imager (Invitrogen) using 2% E-gel SizeSelect gels
(Invitrogen). The cDNA fraction of 300 bp in size (including adapters) was isolated
and puriﬁed. Indexed libraries were pooled and sequenced (paired-end 50 or
100 bp reads) on the Illumina HiSEQ platform to a depth of 41–70 million reads
per sample (QB3 Vincent J. Coates Genomics Sequencing Laboratory). After
removal of PCR duplicates and repeats, there were 21–26 million uniquely
mapping paired-end reads (37–61%).
Mapping and analysis of RNA-seq data. All samples were mapped using
Tophat2 (refs 63,64) with Bowtie2 (ref. 64) as the underlying alignment tool. The
input Illumina fastq ﬁles consisted of paired-end reads with each end containing
100 bp (except for 2 samples with 50 bp of paired-end reads). For equivalency,
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100-bp reads were trimmed to 50 bp before mapping. The target genome assembly
for the human samples was GRCh37/UCSC-hg19 and Tophat was additionally
supplied with a gene model (using its ‘-GTF’ parameter) with data from the hg19
UCSC KnownGenes track65. For multiple-mapped fragments, only the highest
scoring mapping determined by Bowtie2 was kept. Only mappings with both read
ends aligned were kept. Potential PCR duplicates (mappings of more than one
fragment with identical positions for both read ends) were removed with the
samtools ‘rmdup’66 function, keeping only one of any potential duplicates.
The ﬁnal set of mapped paired-end reads for a sample were converted to
position-by-position coverage of the relevant genome assembly using the bedtools
‘genomeCoverageBed’ function67. To determine the count of fragments mapping to
a gene, the position-by-position coverage was summed over the exonic positions of
the gene. This gene total coverage was divided by a factor of 100, to account for the
100-bp of coverage induced by each mapped paired-end fragment (50 bp from each
end) and rounded to an integer. This was calculated for each gene in the UCSC
Known Gene set. For input to DESeq68, all genes with non-zero counts in any
sample were considered. Two replicates of each sample were combined per
the DESeq methodology. SpliceTrap69 was used to analyse splicing changes with
the parameters j15, ch0.1, ir0.1 and IRMyes.
For mapping of reads that are chimeric to the reference genome70, to identify
the translocation breakpoint on chr6 we used STAR-Fusion https://github.com/
STAR-Fusion/. Non-splice junction reads from the macrophage samples that
mapped from the QKI gene on chr6 to any location on chr5 were inspected and
several were found, which mapped from QKI intron 4 to a site that is strongly
transcribed from chr5 in the patient but not at all in her sibling.
Genome-wide computational analysis for RNA motifs. Human mature mRNA
sequences were downloaded from UCSC RefSeq database (hg19). Computational
screening was performed for the QRE motif, UACUAAY N1-20 UAAY, and
counts calculated for the longest annotated transcript. After cross-referencing these
transcripts with either the transcripts annotated on the microarray or the RNA-seq,
we annotated the number or QREs in the Supplementary Data. Transcripts of
which we were unable to assess whether they contain one or more QREs, we
annotated as NA and these were excluded from analysis to generate the CDF plots
in Figs 3j and 5h. To generate the Venn diagrams and scatterplots for the RNA-seq
of monocytes and macrophages (Fig. 3g,i), a ±1.5-fold change cutoff was applied
together with a minimal expression cutoff of patientþ sibling Z1 CPM, to avoid
artiﬁcially large fold changes due to very low expression values. To generate the
Venn diagrams and scatterplots for the THP-1-derived expression data (Fig. 5e, g),
we applied a ±1.5-fold change cutoff and applied a DESeq-derived q-value cutoff
of qr0.05.
MISO analysis. Mixture of isoforms (MISO) analysis was used to assess, quantify
and visualize alternative transcripts based on RNA-seq data. Sequences obtained
from RNA-seq were aligned using TopHat2 to the human genome v19 tran-
scriptome (annotation-set kindly provided by Dr Christopher Burge, MIT,
Cambridge, USA). Using the alignment ﬁles (BAM ﬁles), MISO analyses was
performed on our RNA-seq paired-end sequencing data to identify alternative
splicing events, as previously described71. Second, an annotation set containing only
exons surrounding the splicing event were included in the analysis to generate
a more in-depth analysis of select splicing events. A pairwise comparison was
performed using the sibling and patient monocyte and macrophage on both the full
and selected annotation sets. Additional visualization was performed using the
sashimi plot subpackage from MISO, while modiﬁcations in the plotting procedure
were made to allow visualization of supplementary annotation tracks including
ACTAA and QKI PAR-CLIP sites, along with RefSeq transcripts that deﬁne the
event at (https://github.com/wyleung/rnaveer).
Western blot analysis. Polyacrylamide gel electrophoresis was used to resolve
proteins from cellular lysates harvested in RIPA buffer. Protein determinations
(BCA) were performed to ensure equal loading of protein on a per-sample basis.
QKI-5, -6 and -7 were detected using primary mouse monoclonal antibodies that
target pan-QKI (1:1,000, N73/168; UC Davis/NIH NeuroMab Facility), QKI-5
(1:1,000, N195A/16; UC Davis/NIH NeuroMab Facility), QKI-6 (1:1,000,
N182/17; UC Davis/NIH NeuroMab Facility) or QKI-7 (1:1,000, N183/15.1;
UC Davis/NIH NeuroMab Facility), or polyclonal antibodies targeting QKI-5
(1:1,000, AB9904; Millipore, Amsterdam, The Netherlands), QKI-6 (1:2,000,
AB9906; Millipore) and QKI-7 (1:2,000, AB9908; Millipore). For loading
references, rabbit polyclonal antibodies were used to detect b-actin or Histone H3
(both 1:4,000; Abcam, Cambridge, UK). All gels were run and blotted with
Bio-Rad TGX pre-cast gels and blotted on nitrocellulose 0.2 mm using the
Bio-Rad TurboBlot system (Bio-Rad Laboratories). Full blots are shown in
Supplementary Fig. 7.
Quantiﬁcation of pre-mRNA expression levels by PCR. RNA was harvested
from monocytes and macrophages using Trizol reagent (Thermo Fisher
Scientiﬁc). Standard mouse and human cDNA was made using oligo-dT primers
(Invitrogen), whereas cDNA for alternative splicing studies was synthesized using
random primers (Invitrogen). Primer sets designed for speciﬁc pre-mRNA
ampliﬁcation by quantitative RT–PCR analysis are provided in Supplementary
Table 1. Quantitative RT–PCR analysis for designated mRNA products was
performed using SYBR Green master mix (Bio-Rad, Veenendaal, The
Netherlands). For optimal resolution of pre-mRNA splicing patterns, samples
were run on an Agilent 2100 bioanalyser (Agilent), with full images provided in
Supplementary Figs 8–10.
Statistics. For all experiments, N deﬁned the number of biological replicates. All
in vitro and in vivo results were analysed using GraphPad software with either a
Student’s t-test or analysis of variance (with a Bonferonni post test being used). All
results are expressed as mean±s.e.m. Differences in P-valueso0.05 oro0.01 were
considered signiﬁcant and indicated as follows: *Po0.05 or **Po0.01, respectively.
Ethics. Informed consent was obtained for all patient-derived samples. Approval
for these studies was provided by the relevant medical ethics committees, namely
Maastricht University Medical Center, The Netherlands (Professor Dr E.A.L.
Biessen), for immunohistochemical studies, and Leuven University Hospital,
Belgium (Professor Dr H. Van Esch), for the QKI haploinsufﬁcient and
control materials. All mouse experiments were approved by the regulatory
authorities of the Leiden University and were in compliance with the Dutch
Government Guidelines.
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